Immix Biopharma (IMMX) Change in Accured Expenses (2021 - 2026)

Immix Biopharma has disclosed Change in Accured Expenses across 6 years of filings, most recently posting $432207.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $432207.0, up 67.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 56.11% YoY), and the FY2025 annual result was $1.0 million, down 76.66% from the prior year.
• Change in Accured Expenses came in at $432207.0 for Q1 2026 at Immix Biopharma, up from -$790864.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q4 2024 to a low of -$1.8 million in Q2 2024.
• The 5-year median for Change in Accured Expenses is $451957.0 (2023), against an average of $552423.9.
• Peak annual rise in Change in Accured Expenses reached 908.74% in 2024, while the deepest fall reached 292.53% in 2024.
• Immix Biopharma's Change in Accured Expenses stood at -$170024.0 in 2022, then surged by 602.41% to $854219.0 in 2023, then soared by 167.04% to $2.3 million in 2024, then tumbled by 134.67% to -$790864.0 in 2025, then jumped by 154.65% to $432207.0 in 2026.
• The last three Change in Accured Expenses figures came in at $432207.0 (Q1 2026), -$790864.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.